论文部分内容阅读
目的为把握当前世界各国海洋药物专利技术的竞争态势,为我国海洋药物研发、管理工作提供宏观概览和研发思路。方法对Derwent Innovation Index数据库2004-2008年收录的抗癌、抗心脑血管疾病、抗菌抗病毒和抗老年痴呆症等4种海洋药物的国际专利进行了系统的检索和分析。结果抗癌和抗心脑血管病药物的专利数量最多,分别占总量的41.9%和40.8%;A61K(医药)和A61P(化合物或药物制剂的治疗活性)是海洋药物专利最集中的技术领域,专利申请量分别为1302件和1264件;美国、中国和日本是海洋药物最重要的专利技术来源国,优先权专利数量分别为584件、254件和247件;美国、加拿大和日本的PCT国际专利申请量最多,分别为547件、129件和93件,而中国的PCT国际专利申请量只有19件;天津天士力制药公司、先灵制药公司和拜耳医药保健公司是海洋药物专利申请量最多的结构,申请量分别为58件、55件和46件,但天士力的PCT国际专利申请量为0,与其他跨国医药企业相比还有较大的差距。结论美国和日本是当前海洋药物研发实力最强的国家,无论是PCT国际专利申请量,还是核心专利拥有量,都明显领先于其他国家/地区。虽然我国的海洋药物专利总量的世界排名比较靠前,但是PCT国际专利申请的比例还非常低,专利技术的国际影响力还非常有限,因此应该根据我们的国情有侧重的选择几个技术领域作为突破口,以形成我国海洋药物研发的特色。
Objective To grasp the current competitive situation of marine drugs in various countries in the world and provide a macro overview and research ideas for the development and management of marine drugs in China. Methods The international patent of four kinds of marine drugs such as anti-cancer, anti-cardiovascular and cerebrovascular diseases, antibacterial and anti-virus and anti-dementia included in Derwent Innovation Index database was systematically searched and analyzed in 2004-2008. Results The number of anti-cancer and anti-cardiovascular drugs accounted for 41.9% and 40.8% of the total respectively. A61K (medicine) and A61P (therapeutic activity of compounds or pharmaceutical preparations) were the most concentrated technical fields of marine medicine patents , Respectively, and the number of patent applications was 1302 and 1264 respectively. The United States, China and Japan were the most important source countries of patented marine medicine with the number of priority patents of 584, 254 and 247 respectively. The PCT of the United States, Canada and Japan The largest number of international patent applications were 547, 129 and 93 respectively, compared with only 19 for PCT international patent applications in China. Tianjin Tasly Pharmaceutical Co., Ltd. and Schering-Plow Pharmaceuticals and Bayer HealthCare filed the largest number of patent applications for marine drugs The number of applications was 58, 55 and 46 respectively, but Tasly’s PCT international patent application is 0, which is still far behind other multinational pharmaceutical companies. Conclusions The United States and Japan are the countries with the strongest R & D strength in marine drugs. They are significantly ahead of other countries in terms of both the number of PCT international patent applications and the core patent ownership. Although the total number of marine medicine patents in our country is relatively high in the world rankings, the proportion of PCT international patent applications is still very low and the international influence of patent technology is still very limited. Therefore, several technical fields should be selected according to our national conditions As a breakthrough to form the characteristics of China’s marine drug research and development.